Guest guest Posted September 17, 2005 Report Share Posted September 17, 2005 by Niles http://www.pharmalive.com/magazines/medad/view.cfm?articleID=2478 Leadership in major markets & experienced its 72nd year of consecutive sales growth in 2004. Last year marked the completion of two compete decades of consecutive double-digit earnings increases, excluding special charges. The company achieved a strong, balanced performance in 2004, posting record results in sales, earnings, and cash flow. J & J's medical-devices business segment will become much larger after the completed acquisition by year-end 2005 of Guidant Corp., which generated sales of $3.8 billion in 2004. Sporanox, for fungal infections, generated 2004 sales of $655 million, an increase of 15.5% compared with 2003. In first-half 2005, sales for Sporanox were up 2% to $305 million, with a decrease of 51.7% in U.S. markets. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.